FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Reporters Urged to Probe FDA Transparency

The Association of Health Care Journalists urges its journalist members to look deeper into FDAs use of advisory committees in its regulatory decision...

latest-news-card-1
Human Drugs

Calcium Carbonate OK for Use in Supplements

Federal Register final rule: FDA amends the color additive regulations to allow calcium carbonates use in dietary supplement tablets and capsules.

latest-news-card-1
Federal Register

Guide on Pediatric Study Ethical Considerations

Federal Register notice: FDA posts a draft guidance entitled Ethical Considerations for Clinical Investigations of Medical Products Involving Children...

latest-news-card-1
Medical Devices

New Regulatory Paradigm Needed for Device Software: FDA

FDA concludes after ending a recent pilot program on software as a medical device that a new regulatory paradigm is needed to regulate such devices.

latest-news-card-1
Human Drugs

3 Biocon Biologics FDA-483s Posted

FDA posts three Form FDA-483s issued to Indias Biocon Biologics following three on-site August inspections at the companys seven manufacturing sites i...

latest-news-card-1
Human Drugs

OGD Director Choe Leaving FDA Next Month

CDER Office of Generic Drugs director Sally Choe decides to leave FDA effective 10/8 to pursue opportunities outside the agency.

latest-news-card-1
Human Drugs

CDER Adds Cannabis Advisor in Directors Office

Former New York cannabis programs director Norman Birenbaum joins CDERs Office of the Center Director as a senior public health advisor on cannabis is...

latest-news-card-1
Federal Register

Guide on Exclusions for Naloxone Distribution

Federal Register notice: FDA makes available a final guidance entitled Exemption and Exclusion from Certain Requirements of the Drug Supply Chain Secu...

latest-news-card-1
Federal Register

Regulatory Review Period for Nurtec ODT

Federal Register FDA determines for patent extension purposes the regulatory review period for Biohaven Pharmaceuticals migraine drug Nurtec ODT (rime...

latest-news-card-1
Federal Register

Info Collection on Pediatric Device Survey

Federal Register notice: FDA seeks comments on a new information collection involving a pediatric device survey.